EMBCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends September 30
Embecta Corp.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.21−0.06 (-0.96%)
Close on Oct 19, 2026
- Market cap
- $363.36M
- P/E (TTM)
- 4.2
- Dividend yield
- 9.66%
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
62.6%−7.6 pts over 5 years
Operating margin
22.4%−22.4 pts over 5 years
Net margin
8.8%−30.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -3.8% | -1.5% | -0.1% | – | |
| Gross profit | -7.9% | -4.4% | -2.4% | – | |
| Operating income | +45.1% | -7.9% | -13.0% | – | |
| Net income | +21.8% | -24.7% | -25.9% | – | |
| EPS, diluted | +20.9% | -25.3% | -26.4% | – | |
| Free cash flow | +816.6% | -22.3% | -16.8% | – | |
| Dividend per share | 0.0% | +58.7% | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 74.4% | -13.7% | |
| Return on assets | – | – | 8.0% | |
| Current ratio | – | – | 2.41 | |
| Debt to equity | – | – | -2.15 | |
| Net debt to EBITDA | – | – | 4.15× | |
| Inventory turnover | – | – | 2.3× | |
| Capex to revenue | – | 3.9% | 0.9% | |
| Diluted shares | – | 57M | 59M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Embecta generated $1.16B from operations and spent $224.50M on capital expenditure, dividends and share buybacks. 50% of that went back into the business.
Generated
$1.16B
Used
$224.50M
Capital expenditure$112.00M50%Dividends$112.50M50%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin8.8%
×Asset turnover0.91×
×Equity multiplier-1.71×
=Return on equity, FY2025-13.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 8.8% | 0.91× | -1.71× | -13.7% |
| FY2024 | 7.0% | 0.90× | -1.60× | -10.0% |
| FY2023 | 6.3% | 0.97× | -1.34× | -8.2% |
| FY2022 | 19.8% | 1.21× | -6.31× | -150.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$95.40M
- Cash generatingOperating cash flow above zero$191.70M
- Return on assets improvedROA up on the prior year6.4% → 7.4%
- Earnings backed by cashOperating cash flow above net income$191.70M vs $95.40M
- Less leverageLong-term debt to assets fell121.8% → 127.3%
- Better liquidityCurrent ratio rose2.03 → 2.41
- No dilutionShare count did not rise58M → 59M
- Gross margin improvedGross margin up on the prior year65.46% → 62.64%
- More efficientAsset turnover rose0.92 → 0.84